HETEROCYCLIC COMPOUND Russian patent published in 2022 - IPC C07D487/10 C07D498/10 A61K31/407 A61K31/424 A61P21/00 A61P25/00 A61P43/00 A61P29/00 

FIELD: organic chemistry; pharmaceutics.

SUBSTANCE: group of inventions relates to the field of organic chemistry and pharmaceutics; it is intended for use in the treatment of neurodegenerative diseases. A new compound of the formula (I) is presented, where A is C_3-10 cycloalkyl group substituted with 1-3 substitutes selected from (a) phenoxy group optionally substituted with 1-4 substitutes selected from (i) halogen atom, and (ii) optionally halogenated C_1-6 alkyl group, (b) phenoxy-C_1-6 alkyl group optionally substituted with 1-4 substitutes selected from (i) halogen atom, and (ii) optionally halogenated C_1-6 alkyl group, (c) benzyloxy group optionally substituted with 1-4 substitutes selected from (i) halogen atom, and (ii) optionally halogenated C_1-6 alkyl group, and (d) benzyloxy-C_1-6 alkyl group optionally substituted with 1-4 substitutes selected from (i) halogen atom, and (ii) optionally halogenated C_1-6 alkyl group, and optionally additionally substituted with 1-3 C_1-6 alkyl groups; L is a bond or C_1-3 alkylene group; ring D is 4- or 5-element nitrogen-containing heterocycle; n is equal to 1 or 2; X is -O- or -CH₂-; and both R^a and R^b are hydrogen atoms; or its pharmaceutically acceptable salt. In addition, specific compounds-derivatives of the formula (I), a drug, which is a monoacylglycerolipase inhibitor, containing the specified compound, as well as a method for inhibition of monoacylglycerolipase in a mammal, including administration to a mammal of effective amount of the compound or salt according to cl. 1, are described.

EFFECT: group of inventions provides effective inhibition of monoacylglycerolipase in a mammal.

9 cl, 5 tbl, 67 ex